 | |
| Clinical data | |
|---|---|
| Other names | 4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H16N2O2 |
| Molar mass | 208.261 g·mol−1 |
| 3D model (JSmol) | |
| |
Safrazine (Safra) is a non-selective,irreversiblemonoamine oxidase inhibitor (MAOI) of thehydrazine class that was introduced as anantidepressant in the 1960s, but has since been discontinued alongside several old generation MAOIs in favor of the invention of RIMAs and more efficacious treatments for depression in general.[1]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
